William Small1, Jennifer L James2, Timothy D Moore3, Dan J Fintel4, Stephen T Lutz5, Benjamin Movsas6, Mohan Suntharalingam7, Yolanda I Garces8, Robert Ivker9, John Moulder10, Stephanie Pugh2, Lawrence B Berk11. 1. Department of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University. 2. NRG Oncology Statistics and Data Management Center, Philadelphia, PA. 3. Columbus Community Clinical Oncology Program, Columbus. 4. Division of Cardiology, Northwestern University Hospital, Chicago, IL. 5. Blanchard Valley Radiation Oncology, Findlay, OH. 6. Department of Radiation Oncology, Henry Ford Health System, Detroit. 7. University of Maryland, Baltimore, MD. 8. Radiation Oncology Division, Mayo Clinic, Rochester, MN. 9. Newark Beth Israel Medical Center, Newark, NJ. 10. Medical College of Wisconsin, Milwaukee, WI. 11. H. Lee Moffitt Cancer Center, Tampa, FL.
Abstract
OBJECTIVES: The primary objective of NRG Oncology Radiation Therapy Oncology Group 0123 was to test the ability of the angiotensin-converting enzyme inhibitor captopril to alter the incidence of pulmonary damage after radiation therapy for lung cancer; secondary objectives included analyzing pulmonary cytokine expression, quality of life, and the long-term effects of captopril. MATERIALS AND METHODS:Eligible patients included stage II-IIIB non-small cell lung cancer, stage I central non-small cell lung cancer, or limited-stage small cell. Patients who met eligibility for randomization at the end ofradiotherapy received either captopril or standard care for 1 year. The captopril was to be escalated to 50 mg three times a day. Primary endpoint was incidence of grade 2+ radiation-induced pulmonary toxicity in the first year. RESULTS:Eighty-one patients were accrued between June 2003 and August 2007. Given the low accrual rate, the study was closed early. No significant safety issues were encountered. Eight patients were ineligible for registration or withdrew consent before randomization and 40 patients were not randomized postradiation. Major reasons for nonrandomization included patients' refusal and physician preference. Of the 33 randomized patients, 20 were analyzable (13 observation, 7 captopril). The incidence of grade 2+ pulmonary toxicity attributable to radiation therapy was 23% (3/13) in the observation arm and 14% (1/7) in the captopril arm. CONCLUSIONS: Despite significant resources and multiple amendments, NRG Oncology Radiation Therapy Oncology Group 0123 was unable to test the hypothesis that captopril mitigates radiation-induced pulmonary toxicity. It did show the safety of such an approach and the use of newer angiotensin-converting enzyme inhibitors started during radiotherapy may solve the accrual problems.
RCT Entities:
OBJECTIVES: The primary objective of NRG Oncology Radiation Therapy Oncology Group 0123 was to test the ability of the angiotensin-converting enzyme inhibitor captopril to alter the incidence of pulmonary damage after radiation therapy for lung cancer; secondary objectives included analyzing pulmonary cytokine expression, quality of life, and the long-term effects of captopril. MATERIALS AND METHODS: Eligible patients included stage II-IIIB non-small cell lung cancer, stage I central non-small cell lung cancer, or limited-stage small cell. Patients who met eligibility for randomization at the end of radiotherapy received either captopril or standard care for 1 year. The captopril was to be escalated to 50 mg three times a day. Primary endpoint was incidence of grade 2+ radiation-induced pulmonary toxicity in the first year. RESULTS: Eighty-one patients were accrued between June 2003 and August 2007. Given the low accrual rate, the study was closed early. No significant safety issues were encountered. Eight patients were ineligible for registration or withdrew consent before randomization and 40 patients were not randomized postradiation. Major reasons for nonrandomization included patients' refusal and physician preference. Of the 33 randomized patients, 20 were analyzable (13 observation, 7 captopril). The incidence of grade 2+ pulmonary toxicity attributable to radiation therapy was 23% (3/13) in the observation arm and 14% (1/7) in the captopril arm. CONCLUSIONS: Despite significant resources and multiple amendments, NRG Oncology Radiation Therapy Oncology Group 0123 was unable to test the hypothesis that captopril mitigates radiation-induced pulmonary toxicity. It did show the safety of such an approach and the use of newer angiotensin-converting enzyme inhibitors started during radiotherapy may solve the accrual problems.
Authors: Helen B Stone; John E Moulder; C Norman Coleman; K Kian Ang; Mitchell S Anscher; Mary Helen Barcellos-Hoff; William S Dynan; John R Fike; David J Grdina; Joel S Greenberger; Martin Hauer-Jensen; Richard P Hill; Richard N Kolesnick; Thomas J Macvittie; Cheryl Marks; William H McBride; Noelle Metting; Terry Pellmar; Mary Purucker; Mike E Robbins; Robert H Schiestl; Thomas M Seed; Joseph E Tomaszewski; Elizabeth L Travis; Paul E Wallner; Mary Wolpert; Daniel Zaharevitz Journal: Radiat Res Date: 2004-12 Impact factor: 2.841
Authors: Jordan Kharofa; Eric P Cohen; Rade Tomic; Qun Xiang; Elizabeth Gore Journal: Int J Radiat Oncol Biol Phys Date: 2012-01-31 Impact factor: 7.038
Authors: Lawrence B Marks; Soren M Bentzen; Joseph O Deasy; Feng-Ming Spring Kong; Jeffrey D Bradley; Ivan S Vogelius; Issam El Naqa; Jessica L Hubbs; Joos V Lebesque; Robert D Timmerman; Mary K Martel; Andrew Jackson Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Benjamin Movsas; Bhadrasain Vikram; Martin Hauer-Jensen; John E Moulder; Ethan Basch; Stephen L Brown; Lisa A Kachnic; Adam P Dicker; C Norman Coleman; Paul Okunieff Journal: Clin Cancer Res Date: 2010-11-03 Impact factor: 12.531
Authors: A Molteni; J E Moulder; E F Cohen; W F Ward; B L Fish; J M Taylor; L F Wolfe; L Brizio-Molteni; P Veno Journal: Int J Radiat Biol Date: 2000-04 Impact factor: 2.694
Authors: Terence T Sio; Pamela J Atherton; Levi D Pederson; W Ken Zhen; Robert W Mutter; Yolanda I Garces; Daniel J Ma; James L Leenstra; Jean-Claude M Rwigema; Shaker Dakhil; James D Bearden; Sonja J van der Veen; Apar K Ganti; Steven E Schild; Robert C Miller Journal: Int J Radiat Oncol Biol Phys Date: 2018-11-02 Impact factor: 7.038
Authors: Mudit Chowdhary; Derick Okwan-Duodu; Jeffrey M Switchenko; Robert H Press; Jaymin Jhaveri; Zachary S Buchwald; Jim Zhong; Bhavana V Chapman; Ranjit S Bindra; Joseph N Contessa; Henry S Park; James B Yu; Roy H Decker; Jeffrey J Olson; Nelson M Oyesiku; Ross A Abrams; Hui-Kuo G Shu; Walter J Curran; Ian R Crocker; Kirtesh R Patel Journal: J Neurooncol Date: 2017-11-09 Impact factor: 4.130
Authors: Deborah E Citrin; Pataje G S Prasanna; Amanda J Walker; Michael L Freeman; Iris Eke; Mary Helen Barcellos-Hoff; Molykutty J Arankalayil; Eric P Cohen; Ruth C Wilkins; Mansoor M Ahmed; Mitchell S Anscher; Benjamin Movsas; Jeffrey C Buchsbaum; Marc S Mendonca; Thomas A Wynn; C Norman Coleman Journal: Radiat Res Date: 2017-05-10 Impact factor: 2.841
Authors: Guru Prasad Sharma; Brian L Fish; Anne C Frei; Jayashree Narayanan; Tracy Gasperetti; Dana Scholler; Lauren Pierce; Nathan Szalewski; Noah Blue; Meetha Medhora; Heather A Himburg Journal: Int J Radiat Oncol Biol Phys Date: 2022-01-29 Impact factor: 8.013
Authors: Tracy Gasperetti; Tessa Miller; Feng Gao; Jayashree Narayanan; Elizabeth R Jacobs; Aniko Szabo; George N Cox; Christie M Orschell; Brian L Fish; Meetha Medhora Journal: Front Pharmacol Date: 2021-05-17 Impact factor: 5.810